News: Abbott Laboratories (ABT)

ABT on New York Consolidated

42.11USD
22 Aug 2014
Price Change (% chg)

$-0.21 (-0.50%)
Prev Close
$42.32
Open
$42.22
Day's High
$42.33
Day's Low
$42.00
Volume
2,462,384
Avg. Vol
4,945,653
52-wk High
$43.27
52-wk Low
$32.70

Search Stocks
Select another date:

Thu, Aug 7 2014

Mylan presses on with tax-inversion Abbott deal

- Political opposition to tax-inversion deals will not stop Mylan Inc's purchase of some non-U.S. businesses from Abbott Laboratories , Chief Executive Heather Bresch said, even as some companies have backed away from such tax arrangements.

UPDATE 2-Mylan presses on with tax-inversion Abbott deal

* CEO: Tax-inversion deals do not stop companies paying US taxes

Abbott beats profit estimate, infant formulas rebound

- Abbott Laboratories Inc reported better-than-expected quarterly earnings on Wednesday as demand for its recently-recalled infant formulas began to recover and profit margins improved for other business segments.

BRIEF-Abbott CEO says growth for nutritional products, pharmaceuticals "getting back on track"

July 16 - Abbott Laboratories : * CEO, in conference call, says growth for nutritional products, pharmaceuticals

Sanofi held talks with Abbott, Mylan about mature drugs: document

PARIS - Sanofi has held talks with Abbott Laboratories , Mylan and private equity firms over the possible sale of a 6.3 billion euro ($8.5 billion) portfolio of mature drugs, according to an internal document seen by Reuters.

UPDATE 1-Sanofi held talks with Abbott, Mylan about mature drugs -document

* Portfolio has sales of 2.1 bln eur, enterprise value 6.3 bln eur

Sanofi held talks with Abbott, Mylan on mature drugs -document

PARIS, July 16 - Sanofi has held talks with Abbott Laboratories, Mylan and private equity firms over the possible sale of a 6.3 billion euro ($8.5 billion) portfolio of mature drugs, according to an internal document seen by Reuters.

Mylan to buy Abbott generics, cut taxes, in $5.3 billion deal

- Generic drugmaker Mylan Inc said on Monday it would buy Abbott Laboratories' branded specialty and generics business in developed markets outside the United States in a $5.3 billion deal that will bolster its product line and also cut its tax bill.

Abbott CEO says interested in acquiring more medical devices

- Abbott Laboratories <ABT.N) said on Monday it is interested in bolstering its line of medical devices, but it was becoming increasingly difficult to find appropriate and affordable products.

UPDATE 2-Mylan to buy Abbott generics, cut taxes, in $5.3 bln deal

(Adds analyst comments, details of deal, company background, stock prices)

Select another date:
Search Stocks